Craft
  • Home
  •  / Palleon Pharmaceuticals
Palleon Pharmaceuticals

Palleon Pharmaceuticals

Total Funding

$147.6 M

Palleon Pharmaceuticals Summary

Company summary

Overview
Palleon Pharmaceuticals is a biotechnology company focused on developing Glycoimmune Checkpoint inhibitors to treat cancer. The Company’s proprietary Convergence Platform integrates technologies and insights from world-renowned scientific leaders in the fields of glycoscience and human immunology to create a novel approach to treating cancer. By targeting multiple immune cell types, Glycoimmune Checkpoint inhibitors will tackle resistance to first-generation immuno-oncology agents, and make possible a wider range of rational combination therapies to treat cancer. While Palleon is focused primarily on oncology, the Convergence Platform is applicable to other therapeutic areas including infectious diseases, neurodegeneration, inflammation, and fibrosis.
Type
Private
Founded
2016
HQ
Waltham, MA, US | view all locations
Website
http://palleonpharma.com/
Cybersecurity rating
Sectors

Key people

  • Jim Broderick

    Jim Broderick, Chief Executive Officer, Founder

    • Li Peng

      Li Peng, Chief Scientific Officer

    • David Feltquate

      David Feltquate, Chief Medical Officer

    • Carolyn Bertozzi

      Carolyn Bertozzi, Co-Founder

      LocationsView all

      1 location detected

      • Waltham, MA HQ

        United States

        266 2nd Ave

      Footer menu